Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 707 Thousand USD | -96.16% |
| 2022 | 18.39 Million USD | -8.37% |
| 2021 | 20.07 Million USD | 944.87% |
| 2020 | 1.92 Million USD | 102.71% |
| 2019 | -70.82 Million USD | 16.15% |
| 2018 | -84.46 Million USD | -52.38% |
| 2017 | -55.43 Million USD | -2443.85% |
| 2016 | 2.36 Million USD | 160.19% |
| 2015 | -3.92 Million USD | 53.17% |
| 2014 | -8.39 Million USD | -15.28% |
| 2013 | -7.27 Million USD | 34.0% |
| 2012 | -11.02 Million USD | -87.5% |
| 2011 | -5.88 Million USD | 32.32% |
| 2010 | -8.69 Million USD | 2.72% |
| 2009 | -8.93 Million USD | 40.95% |
| 2008 | -15.12 Million USD | -48.94% |
| 2007 | -10.15 Million USD | 61.24% |
| 2006 | -26.2 Million USD | 64.86% |
| 2005 | -74.56 Million USD | -447.23% |
| 2004 | -13.62 Million USD | 66.11% |
| 2003 | -40.2 Million USD | -546.84% |
| 2002 | -6.21 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.37 Million USD | -71.79% |
| 2024 Q1 | 4.85 Million USD | 586.99% |
| 2023 Q3 | -2.99 Million USD | -135.59% |
| 2023 Q4 | 707 Thousand USD | 123.57% |
| 2023 FY | 707 Thousand USD | -96.16% |
| 2023 Q2 | 8.42 Million USD | -8.96% |
| 2023 Q1 | 9.25 Million USD | -49.68% |
| 2022 Q1 | 25.17 Million USD | 25.42% |
| 2022 Q4 | 18.39 Million USD | -34.42% |
| 2022 Q2 | 19.64 Million USD | -21.98% |
| 2022 FY | 18.39 Million USD | -8.37% |
| 2022 Q3 | 28.04 Million USD | 42.77% |
| 2021 Q1 | -72.16 Million USD | -3856.85% |
| 2021 FY | 20.07 Million USD | 944.87% |
| 2021 Q3 | 17.94 Million USD | 236.06% |
| 2021 Q4 | 20.07 Million USD | 11.87% |
| 2021 Q2 | 5.33 Million USD | 107.4% |
| 2020 Q3 | -5.76 Million USD | -167.53% |
| 2020 Q4 | 1.92 Million USD | 133.35% |
| 2020 FY | 1.92 Million USD | 102.71% |
| 2020 Q2 | -2.15 Million USD | 89.41% |
| 2020 Q1 | -20.32 Million USD | 71.31% |
| 2019 Q2 | -3.01 Million USD | 87.41% |
| 2019 Q1 | -23.92 Million USD | 71.67% |
| 2019 Q3 | -1.69 Million USD | 43.78% |
| 2019 FY | -70.82 Million USD | 16.15% |
| 2019 Q4 | -70.82 Million USD | -4081.17% |
| 2018 Q2 | -38.58 Million USD | 16.62% |
| 2018 Q4 | -84.46 Million USD | -11.75% |
| 2018 FY | -84.46 Million USD | -52.38% |
| 2018 Q1 | -46.27 Million USD | 16.52% |
| 2018 Q3 | -75.58 Million USD | -95.91% |
| 2017 Q4 | -55.43 Million USD | 13.37% |
| 2017 FY | -55.43 Million USD | -2443.85% |
| 2017 Q3 | -63.98 Million USD | -2957.4% |
| 2017 Q2 | 2.23 Million USD | -57.47% |
| 2017 Q1 | 5.26 Million USD | 124.13% |
| 2016 Q2 | -12.4 Million USD | -10.62% |
| 2016 Q1 | -11.21 Million USD | -16.92% |
| 2016 Q4 | 2.34 Million USD | 115.5% |
| 2016 FY | 2.36 Million USD | 160.19% |
| 2016 Q3 | -15.15 Million USD | -22.2% |
| 2015 FY | -3.92 Million USD | 53.17% |
| 2015 Q4 | -9.58 Million USD | 30.05% |
| 2015 Q3 | -13.7 Million USD | -29.71% |
| 2015 Q2 | -10.56 Million USD | 49.82% |
| 2015 Q1 | -21.06 Million USD | -151.02% |
| 2014 Q1 | -6.74 Million USD | 7.36% |
| 2014 FY | -8.39 Million USD | -15.28% |
| 2014 Q3 | -11.24 Million USD | -73.91% |
| 2014 Q2 | -6.46 Million USD | 4.15% |
| 2014 Q4 | -8.39 Million USD | 25.35% |
| 2013 Q1 | -20.35 Million USD | -84.56% |
| 2013 Q4 | -7.27 Million USD | -81.93% |
| 2013 Q3 | -4 Million USD | 9.34% |
| 2013 Q2 | -4.41 Million USD | 78.32% |
| 2013 FY | -7.27 Million USD | 34.0% |
| 2012 Q4 | -11.02 Million USD | -27.74% |
| 2012 FY | -11.02 Million USD | -87.5% |
| 2012 Q3 | -8.63 Million USD | -3.94% |
| 2012 Q2 | -8.3 Million USD | 67.97% |
| 2012 Q1 | -25.93 Million USD | -340.92% |
| 2011 Q3 | -6.07 Million USD | 42.66% |
| 2011 Q4 | -5.88 Million USD | 3.19% |
| 2011 Q1 | -29.91 Million USD | -244.25% |
| 2011 FY | -5.88 Million USD | 32.32% |
| 2011 Q2 | -10.59 Million USD | 64.58% |
| 2010 Q2 | -3.72 Million USD | 44.33% |
| 2010 Q4 | -8.69 Million USD | -120.64% |
| 2010 FY | -8.69 Million USD | 2.72% |
| 2010 Q1 | -6.69 Million USD | 25.03% |
| 2010 Q3 | -3.93 Million USD | -5.63% |
| 2009 Q3 | -4.2 Million USD | 20.33% |
| 2009 Q1 | -12.24 Million USD | 19.08% |
| 2009 Q2 | -5.27 Million USD | 56.89% |
| 2009 FY | -8.93 Million USD | 40.95% |
| 2009 Q4 | -8.93 Million USD | -112.46% |
| 2008 Q2 | -10.2 Million USD | 14.28% |
| 2008 Q4 | -15.12 Million USD | 32.39% |
| 2008 Q3 | -22.37 Million USD | -119.33% |
| 2008 Q1 | -11.9 Million USD | -17.17% |
| 2008 FY | -15.12 Million USD | -48.94% |
| 2007 Q2 | -14.69 Million USD | 24.29% |
| 2007 FY | -10.15 Million USD | 61.24% |
| 2007 Q1 | -19.4 Million USD | 25.94% |
| 2007 Q3 | -14.41 Million USD | 1.92% |
| 2007 Q4 | -10.15 Million USD | 29.52% |
| 2006 Q4 | -26.2 Million USD | 27.03% |
| 2006 Q2 | -43.33 Million USD | 19.14% |
| 2006 FY | -26.2 Million USD | 64.86% |
| 2006 Q3 | -35.91 Million USD | 17.12% |
| 2006 Q1 | -53.59 Million USD | 28.13% |
| 2005 Q4 | -74.56 Million USD | -127.27% |
| 2005 Q1 | -44.35 Million USD | -225.5% |
| 2005 Q3 | -32.81 Million USD | 16.65% |
| 2005 Q2 | -39.36 Million USD | 11.25% |
| 2005 FY | -74.56 Million USD | -447.23% |
| 2004 FY | -13.62 Million USD | 66.11% |
| 2004 Q3 | -15.84 Million USD | 0.0% |
| 2004 Q4 | -13.62 Million USD | 13.98% |
| 2003 FY | -40.2 Million USD | -546.84% |
| 2002 FY | -6.21 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 61.071% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 118.532% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 43.62% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 97.805% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 175.293% |
| Better Therapeutics, Inc. | -860 Thousand USD | 182.209% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 102.972% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -115.259% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 84.53% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 112.142% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 77.892% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 77.674% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 85.866% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 99.473% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -294.641% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 94.27% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -61.252% |
| NexImmune, Inc. | -3.13 Million USD | 122.562% |
| Orgenesis Inc. | 21.78 Million USD | 96.754% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 72.974% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 142067.871% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 115.009% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 667.53% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 99.362% |
| Statera Biopharma, Inc. | 14.41 Million USD | 95.096% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 109.308% |
| Trevena, Inc. | 2.25 Million USD | 68.689% |
| Vaxxinity, Inc. | 10.13 Million USD | 93.022% |
| Vaccinex, Inc. | -1.28 Million USD | 154.891% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -105.257% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 94.66% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -882.463% |